FDA panel votes 15-1-1 that Abbott's (ABT) Humira benefit is meaningful
FDA panel votes 15-1-1 that Abbott's (NYSE: ABT) Humira benefit is meaningful. The panel also said Humira has benefit in UC after 8 weeks.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbott Labs (ABT) Tops Q3 EPS by 3c; Raises FY14 EPS Midpoint
- Market Wrap: CPI Outpaces in Sept.; Regulus Ramps on RG-101 Data; AT&T Trims Outlook
- Regulus (RGLS) Impressive RG101 Results Could Transform HCV Treatment, BMO Capital Says
Create E-mail Alert Related CategoriesFDA, General News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!